Flagship launches first UK biotech Quotient with genome sequencing platform

New Flagship Pioneering biotech Quotient Therapeutics has lots to be thankful for this year, namely $50 million in cash, a new U.K. outpost to work from and a formal unveiling as the holiday season approaches. 

The Cambridge startup incubator took the lid off its latest company Tuesday, possibly the last Flagship launch of 2023. Quotient’s focus is on identifying potentially disease-causing genetic discrepancies that crop up in a single person’s body. Co-founder and President Jake Rubens, Ph.D., said that instead of comparing genomes across patients, the biotech aims to compare genomes with cells of a single patient. 

To read more, click here.